Literature DB >> 32530703

Thoracic Visceral Adipose Tissue Area and Pulmonary Hypertension in Lung Transplant Candidates. The Lung Transplant Body Composition Study.

Nadine Al-Naamani1, Hao-Min Pan1, Michaela R Anderson2, Drew A Torigian3, Yubing Tong3, Michelle Oyster1, Mary K Porteous1, Scott Palmer4, Selim M Arcasoy2, Joshua M Diamond1, Jayaram K Udupa3, Jason D Christie1, David J Lederer2,5, Steven M Kawut1.   

Abstract

Rationale: Obesity is associated with an increased risk of pulmonary hypertension (PH); however, regional adipose tissue deposition is heterogeneous with distinct cardiovascular phenotypes.
Objectives: To determine the association of body mass index (BMI) and thoracic visceral and subcutaneous adipose tissue areas (VAT and SAT, respectively) with PH in patients with advanced lung disease referred for lung transplantation.
Methods: We studied patients undergoing evaluation for lung transplantation at three centers from the Lung Transplant Body Composition Study. PH was defined as mean pulmonary artery pressure >20 mm Hg and pulmonary vascular resistance ≥3 Wood units. VAT and SAT were measured on chest computed tomography and normalized to height squared.
Results: One hundred thirty-seven (34%) of 399 patients included in our study had PH. Doubling of thoracic VAT was associated with significantly lower pulmonary vascular resistance (β, -0.24; 95% confidence interval [95% CI], -0.46 to -0.02; P = 0.04), higher pulmonary arterial wedge pressure (β, 0.79; 95% CI, 0.32 to 1.26; P = 0.001), and decreased risk of PH (relative risk, 0.86; 95% CI, 0.74 to 0.99; P = 0.04) after multivariate adjustment. Vaspin levels were higher in patients without PH (median, 101.8 vs. 92.0 pg/ml; P < 0.001) but did not mediate the association between VAT and the risk of PH. SAT and BMI were not independently associated with risk of PH.Conclusions: Lower thoracic VAT was associated with a higher risk of PH in patients with advanced lung disease undergoing evaluation for lung transplantation. The role of adipokines in the pulmonary vascular disease remains to be evaluated.

Entities:  

Keywords:  adipose tissue; advanced lung disease; pulmonary hypertension; vaspin

Year:  2020        PMID: 32530703      PMCID: PMC7640728          DOI: 10.1513/AnnalsATS.202003-247OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  52 in total

1.  A modified poisson regression approach to prospective studies with binary data.

Authors:  Guangyong Zou
Journal:  Am J Epidemiol       Date:  2004-04-01       Impact factor: 4.897

2.  Relationship between adipocyte size and adipokine expression and secretion.

Authors:  Thomas Skurk; Catherine Alberti-Huber; Christian Herder; Hans Hauner
Journal:  J Clin Endocrinol Metab       Date:  2006-12-12       Impact factor: 5.958

3.  Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue.

Authors:  Yoichiro Hirata; Minoru Tabata; Hirotsugu Kurobe; Tatsuo Motoki; Masashi Akaike; Chika Nishio; Mayuko Higashida; Hiroaki Mikasa; Yutaka Nakaya; Shuichiro Takanashi; Takashi Igarashi; Tetsuya Kitagawa; Masataka Sata
Journal:  J Am Coll Cardiol       Date:  2011-07-12       Impact factor: 24.094

Review 4.  Pulmonary hypertension in chronic lung diseases.

Authors:  Werner Seeger; Yochai Adir; Joan Albert Barberà; Hunter Champion; John Gerard Coghlan; Vincent Cottin; Teresa De Marco; Nazzareno Galiè; Stefano Ghio; Simon Gibbs; Fernando J Martinez; Marc J Semigran; Gerald Simonneau; Athol U Wells; Jean-Luc Vachiéry
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

5.  Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study.

Authors:  Ravi V Shah; Venkatesh L Murthy; Siddique A Abbasi; Ron Blankstein; Raymond Y Kwong; Allison B Goldfine; Michael Jerosch-Herold; João A C Lima; Jingzhong Ding; Matthew A Allison
Journal:  JACC Cardiovasc Imaging       Date:  2014-11-05

6.  A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha.

Authors:  Takayoshi Suganami; Junko Nishida; Yoshihiro Ogawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-08-25       Impact factor: 8.311

7.  The ventricular epicardial fat is related to the myocardial mass in normal, ischemic and hypertrophic hearts.

Authors:  Domenico Corradi; Roberta Maestri; Sergio Callegari; Paolo Pastori; Matteo Goldoni; Tu Vinh Luong; Cesare Bordi
Journal:  Cardiovasc Pathol       Date:  2004 Nov-Dec       Impact factor: 2.185

8.  Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway.

Authors:  Chang Hee Jung; Woo Je Lee; Jenie Yoonoo Hwang; So Mi Seol; Yun Mi Kim; Yoo La Lee; Joong-Yeol Park
Journal:  Biochem Biophys Res Commun       Date:  2011-08-27       Impact factor: 3.575

Review 9.  Potential beneficial effect of some adipokines positively correlated with the adipose tissue content on the cardiovascular system.

Authors:  Magdalena Sawicka; Joanna Janowska; Jerzy Chudek
Journal:  Int J Cardiol       Date:  2016-07-07       Impact factor: 4.164

10.  Chest Fat Quantification via CT Based on Standardized Anatomy Space in Adult Lung Transplant Candidates.

Authors:  Yubing Tong; Jayaram K Udupa; Drew A Torigian; Dewey Odhner; Caiyun Wu; Gargi Pednekar; Scott Palmer; Anna Rozenshtein; Melissa A Shirk; John D Newell; Mary Porteous; Joshua M Diamond; Jason D Christie; David J Lederer
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

View more
  2 in total

1.  The Association of Body Mass Index With the Risk of Pulmonary Hypertension in Adults: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Shoufang Pu; Lidan Yin; Bi Wen; Juan He
Journal:  Front Med (Lausanne)       Date:  2022-01-25

Review 2.  Obesity, estrogens and adipose tissue dysfunction - implications for pulmonary arterial hypertension.

Authors:  Kirsty M Mair; Rosemary Gaw; Margaret R MacLean
Journal:  Pulm Circ       Date:  2020-09-18       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.